CluenexWest Pharmaceutical Services WST
West Pharmaceutical Services scores good on business quality (6.6 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What West Pharmaceutical Services does
West Pharmaceutical Services manufactures proprietary containment and delivery systems for injectable drugs, selling directly to pharmaceutical and biotech developers who rely on its packaging to maintain sterility.
- What it does best
West dominates injectable component manufacturing with a gross margin of 36.8% outpacing peer WAT at 50.9% in some segments while embedding its proprietary packaging directly into drug regulatory filings, creating extreme switching costs.
- The main risk
Revenue growth sits at a sluggish 6.3% as inventory normalization across pharmaceutical clients weighs on volume, leaving the business vulnerable to prolonged client destocking cycles.
Quality, check by check
Scored against its own industry, from company filings.
Operating margin of 21.6% and net margin of 17.0% reflect solid returns, though profitability remains stable rather than expanding as scale benefits are currently offset by flat volume growth.
Regulatory lock-in protects its enterprise drugmaker base, reflected in an operating margin ranking in the 68th sector percentile that rivals cannot easily replicate due to strict FDA validation.
Revenue grew to $3.3B, marking a modest 6.3% rate that shows a slow recovery compared to the volatile historical trajectory seen in prior years.
Debt-to-equity of 0.1x and interest coverage of 159x mean debt costs are a rounding error, supported by $791M in cash that leaves the balance sheet exceptionally strong.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
1 sold $2.8M outside pre-planned sales.
Our sealed record on WST
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
West Pharmaceutical Services scores good on the Cluenex quality check (6.6 of 10), measured against its own industry. Profitability is fair, moat strong, growth slow and financial health strong.
In the last 90 days of SEC Form 4 filings: 1 sold $2.8M outside pre-planned sales.
Oct 21, 2026, before the open.
See WST today
- Today's verdict on WST, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “West Pharmaceutical Services (WST)”, https://cluenex.com/stocks/wst/, data as of Oct 10, 2026.